ROSEVILLE, Calif.--(BUSINESS WIRE)--Dutton Associates updates its coverage of Neurobiological Technologies (Nasdaq:NTII) maintaining a Strong Speculative Buy rating and a 12-month target price of $4. The 11-page report by Dutton senior analyst Denise T. Resnik, M.S. is available at www.jmdutton.com as well as from First Call, Bloomberg Professional, Capital IQ, Zacks, Reuters, Knobias, and other leading financial portals.
